



LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. 05882.0147.NPUS01	APPLICATION NO. 10/633,486
APPLICANT Daniel Afar, et al.			
FILING DATE July 31, 2003		GROUP 1623	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
/AW/	1.	Ross, J.S. and Fletcher, J.A. "The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy." <i>Stem Cells</i> , 16:413-428 (1998)					
	2.	Leget, Z.A. and Czuczman, M.S. "Use of rituximab, the new FDA-approved antibody." <i>Curr. Opin. Oncol.</i> 10:548-551 (1998).					
↓	3.	Maloney, D.G. et al. "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma." <i>Blood</i> , 90:2188-2195 (1997).					
	4.						
	5.						
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						

05/14/2007

/Anuradha Waghray/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.